Obituary: India loses R&D champion as Dr Anji Reddy dies aged 72
This article was originally published in Scrip
Executive Summary
"I hate the term Third World country and maybe if we produce 30 Merck-like companies in India then this nomenclature will be dropped," Dr Anji Reddy, founder and chairman of Dr Reddy's Laboratories (DRL), once said at a lecture in Mumbai. This was quite characteristic of the man who always believed Indian firms and R&D are world class and that India would one day emerge as a nucleus of drug discovery.
You may also be interested in...
Events And Losses That Shook India Pharma In The Decade
The past decade witnessed a bout of pharma 'shock and awe' events in India, some of which still reverberate across the industry. The period also marked the death of doyens of the Indian pharmaceutical sector, including the founders of Dr Reddy’s and Lupin.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet